Skip to main content
Menu closed
Man at pool in swim trunks with his towel around his shoulders

For adults with obesity, or some adults with overweight and weight-related medical problems

Change starts with Zepbound*

*Along with reduced-calorie diet and increased physical activity.

Compare to a placebo Compare to a competitor

For adults with obesity, or some adults with overweight and weight-related medical problems

Change starts with Zepbound*

*Along with reduced-calorie diet and increased physical activity.

Compare to a placebo Compare to a competitor
Woman in sleeveless blue dress with hands on her hips

People taking
Zepbound 15 mg lost
up to

People taking Zepbound 15mg lost up to 48lbs (~21% weight loss). Individual results may vary.

(~21% weight loss)†

Individual results may vary.


Zepbound helps adults with obesity lose weight and keep it off. It is proven to deliver significant and sustained weight loss.†‡

Zepbound is not for cosmetic weight loss.

†Along with diet and exercise.

‡In a 72-week study of adults without diabetes, average weight loss was 15.0% (34 lbs) for 5 mg, 19.5% (44 lbs) for 10 mg, 20.9% (48 lbs) for 15 mg, and 3.1% (7 lbs) for placebo. Average starting weights were 226.8 lbs for 5 mg, 233.3 lbs for 10 mg, 232.8 lbs for 15 mg, and 231.0 lbs for placebo. In a 72-week study of adults with diabetes, average weight loss was 12.8% (28 lbs) for 10 mg, 14.7% (33 lbs) for 15 mg, and 3.2% (7 lbs) for placebo. Average starting weights were 222.4 lbs for 10 mg, 219.6 lbs for 15 mg, and 224.2 lbs for placebo.

58lbs

§Individual results may vary. In a 72-week study of adults without diabetes, the percent who saw ≥25% body weight loss (57-58 lbs):

  • Zepbound 5 mg: 15.3%
  • Zepbound 10 mg: 32.3%
  • Zepbound 15 mg: 36.2%
  • Placebo: 1.5%

Results are based on less-rigorous assessment and may be due to chance. Factors beyond Zepbound may have contributed to weight loss.

4-6x more weight loss with Zepboundǁ
than diet and exercise alone

In a 72 week study, weight loss was 15% for 5 mg dose, 20.9% for 15 mg dose compared to 3.1% for placebo

ǁAlong with diet and exercise.

Average percent weight loss observed across different doses at 17 months

Continued use of Zepbound MTD (10 mg or 15 mg) for significant weight loss vs placebo

In a study lasting 88 weeks, adults without diabetes were treated with increasing doses of Zepbound. On average, participants experienced weight loss after 36 weeks—the first phase of the study. Participants were then randomly assigned to either continue receiving Zepbound or switch to placebo. Those who stayed on Zepbound MTD (10 mg or 15 mg) continued losing weight while those who received placebo regained weight.

Zepbound is not for cosmetic weight loss.

aTirzepatide and placebo included a reduced-calorie diet and increased physical activity.

bIndividual results may vary. An 88-week study examined adults without diabetes with obesity or overweight and weight-related medical problems. The average starting weight for these participants was 236.6 lbs. For the first 36 weeks, all participants received—and knew they were receiving—Zepbound MTD (10 mg or 15 mg, the max dose a participant could tolerate). Participants who finished this first phase lost an average of 20.9% of their body weight. This phase of the study was less rigorous and factors beyond Zepbound may have contributed to weight loss.

In the more rigorous phase of the study from weeks 36 to 88, participants who remained on Zepbound weighed 186.5 lbs at week 36, on average. They lost an average of 5.5% (10.3 lbs) of their body weight at week 88. Those who were switched to placebo weighed 189.2 lbs at week 36, on average. They gained back an average of 14% (24.6 lbs) body weight at week 88.

MTD=maximum tolerated dose.

See how Zepbound compared to Wegovy® (semaglutide)¶**

Individual results may vary.

Data collected in a less rigorous study so findings are less certain. Factors beyond studied medications may have contributed to weight loss.

Zepbound is not for cosmetic weight loss.

Along with diet and exercise.

**In a 72-week study of adults without diabetes with obesity or overweight and weight-related medical problems, participants on Zepbound MTD (10 mg or 15 mg, the max dose a participant could tolerate) experienced on average a 20.2% (50 Ibs) weight loss compared to an average of 13.7% (33 Ibs) weight loss for participants on Wegovy MTD (1.7 mg or 2.4 mg, the max dose a participant could tolerate). Average starting weights were 248.4 Ibs for Zepbound MTD and 250 Ibs for Wegovy MTD.

MTD=maximum tolerated dose.

Wegovy® is a registered trademark of Novo Nordisk A/S.

Select Safety Information

Zepbound can cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Additional health measures

In a 17-month clinical trial, people who dieted, exercised, and took Zepbound experienced improvements in:††‡‡

Droplet icon with green first-aid symbol
Cholesterol
Blood pressure cuff icon
Blood pressure
Measuring tape icon
Waist size

Some people taking Zepbound also experienced an increase in resting heart rate.

††Zepbound is not for the treatment of cholesterol or blood pressure.
 ‡‡Diet and exercise included a reduced-calorie meal plan and increased physical activity.

Waist size=waist circumference.

Select Safety Information

Zepbound can cause serious side effects, including:

Kidney problems (kidney failure). Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration.

What is Zepbound?

Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound should be used with a reduced-calorie diet and increased physical activity.

  • Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines.
  • It is not known if Zepbound is safe and effective for use in children.

Finally, there’s Zepbound—the first and only weight loss treatment of its kind§§

§§Zepbound activates the receptors of 2 hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

Zepbound tackles an underlying cause of excess weight.

It reduces appetite and how much you eat.

Zepbound works differently than other obesity management medications by activating 2 hormone receptors.ǁǁ
It reduces appetite and food intake.

ǁǁHormone receptors of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

An illustration of a doctor speaking with a patient

Talk to your doctor with confidence

We’re here to make things easier for you—see what questions to ask your doctor and make sure you’re prepared for questions they’ll likely have for you.

A woman looking at her phone and smiling.

Getting the care you need can be quick and accessible

Explore speed, convenience, and access to focused care with independent telehealth or in-person providers through LillyDirect.

In-person care Telehealth

LillyDirect® is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. PP-LX-US-0052 03/2024 ©Lilly USA, LLC 2024. All rights reserved.

Zepbound does not sponsor or organize 5k running events. Running is shown only as an example of exercise.

Woman ziplining

Learn how you could save on Zepbound

Explore savings options

SAFETY SUMMARY WITH WARNINGS

Warning:

Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

  • Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
  • Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.

Zepbound may cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Kidney problems (kidney failure). Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration.

Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.

Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

Depression or thoughts of suicide. You should pay attention to changes in your mood, behaviors, feelings or thoughts. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Common side effects

The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn’t go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using Zepbound

  • Your healthcare provider should show you how to use Zepbound before you use it for the first time.
  • Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea which could increase your risk of low blood sugar. Talk to your healthcare provider about low blood sugar levels and how to manage them.
  • If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound.

Review these questions with your healthcare provider:

❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?

❑ Do you take diabetes medicines, such as insulin or sulfonylureas?

❑ Do you have a history of diabetic retinopathy?

❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?

❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?

❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. It is not known if Zepbound passes into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.

  • Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979).

How to take

  • Read the Instructions for Use that come with Zepbound.
  • Use Zepbound exactly as your healthcare provider says.
  • Use Zepbound with a reduced-calorie diet and increased physical activity.
  • Zepbound is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.
  • Use Zepbound 1 time each week, at any time of the day.
  • Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection.
  • If you take too much Zepbound, call your healthcare provider, seek medical advice promptly, or contact a Poison Center expert right away at 1-800-222-1222.

Zepbound injection is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial.

Learn more

Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979).

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.

ZP CON BS 20DEC2024

Zepbound® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

INDICATIONS

Zepbound® (ZEHP-bownd) is an injectable prescription medicine that may help adults with:

  • obesity, or some adults with overweight who also have weight-related medical problems to lose excess body weight and keep the weight off.
  • moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.

It should be used with a reduced-calorie diet and increased physical activity.

Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.